Castle Biosciences, Inc.

Historical 13F Holders

Symbol
CSTL
CUSIP
14843C105
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 14843C105 since 12/18/2024, newest first.

Filer % of Class Filed
RTW Investments, LP 13G/A Amendment 1
9.3% 5/15/2026
Event 3/31/2026
Portolan Capital Management, LLC 13G/A Amendment 1
4.5% 5/15/2026
Event 3/31/2026
Vanguard Group Inc 13G/A Amendment 3 0% 3/26/2026
Event 3/13/2026
RTW Investments, LP 13G
7.2% 2/17/2026
Event 12/31/2025
Dimensional Fund Advisors LP 13G/A Amendment 1 3.9% 1/21/2026
Event 12/31/2025
Dimensional Fund Advisors LP 13G 5.1% 10/9/2025
Event 9/30/2025
Wasatch Advisors LP 13G/A Amendment 6 3.5% 5/12/2025
Event 3/31/2025
BlackRock, Inc. 13G/A Amendment 4 8.2% 4/23/2025
Event 3/31/2025
Portolan Capital Management, LLC 13G
5.7% 4/14/2025
Event 4/7/2025
Vanguard Group Inc 13G/A Amendment 2 6.5% 1/30/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 5 15.9 k $563 k
2026 Q2 179 28.3 M $692 M
2026 Q1 192 27.6 M $678 M
2025 Q4 201 27.3 M $1.06 B
2025 Q3 178 26.7 M $609 M
2025 Q2 156 26.7 M $545 M
2025 Q1 187 25.9 M $517 M
2024 Q4 213 26.6 M $706 M
2024 Q3 203 26.0 M $740 M
2024 Q2 172 25.5 M $553 M
2024 Q1 161 26.4 M $584 M
2023 Q4 162 24.5 M $529 M
2023 Q3 143 23.2 M $392 M
2023 Q2 138 23.0 M $317 M
2023 Q1 155 22.1 M $503 M
2022 Q4 162 22.8 M $536 M
2022 Q3 166 21.9 M $572 M
2022 Q2 152 22.6 M $495 M
2022 Q1 164 22.8 M $1.02 B
2021 Q4 167 21.5 M $919 M
2021 Q3 194 21.6 M $1.43 B
2021 Q2 188 20.8 M $1.52 B
2021 Q1 182 21.3 M $1.50 B
2020 Q4 179 20.0 M $1.29 B
2020 Q3 150 13.5 M $692 M
2020 Q2 129 11.8 M $444 M
2020 Q1 93 7.40 M $221 M
2019 Q4 70 5.17 M $178 M
2019 Q3 58 4.87 M $88.1 M